Statins and elevated liver tests: What's the fuss?

Journal of Family Practice

Volumn 57, Issue 7, 2008, Pages 449-452

  Onusko, Edward ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Family Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DRUG CONTRAINDICATION; DRUG INFORMATION; DRUG MEGADOSE; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERCHOLESTEROLEMIA; LABORATORY TEST; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER INJURY; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTION; PRESCRIPTION; SHORT SURVEY; SIDE EFFECT; TREATMENT WITHDRAWAL;

ADULT; ALANINE TRANSAMINASE; ANTICHOLESTEREMIC AGENTS; ASPARTATE AMINOTRANSFERASES; ATTITUDE OF HEALTH PERSONNEL; FEMALE; HUMANS; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 48249111350     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (15)

1. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
2. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult treatment Panel III guidelines. Circulation. 2004;110:227-239.
3. Kashani MS, Phillips CO, Foody JM, et al. Risks associated with statin therapy. Circulation. 2006; 114:2788-2797.
4. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol. 2007;49:1753-1762.
5. Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease. Circulation. 2007;115:700-707.
6. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354:731-739.
7. Smith CC, Bernstein LI, Davis RB, et al. Screening for statin-related toxicity. Arch Intern Med. 2003;163:688-692.
8. Charles EC, Olson KL, Sandhoff BG, et al. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med. 2005;118:618-624.
9. American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of liver chemistry tests. Gastroenterology. 2002;123:1364.
10. Weismantel D. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents? J Fam Pract, 2001; 50:927-928.
11. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Advisory on the use and safety of statins. Circulation. 2002;106:1024-1028.
12. Alsheikh-Ali AA, Maddurkuri PV, Han H, Karas RH. Effect of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol. 2007;50:409-418.
13. In brief: Zetia and Vytorin: The ENHANCE study. Med Lett Drugs Ther. 2008;50(1278):5.
14. Bayard M, Holt J, Boroughs E. Nonalcoholic fatty liver disease. Am Fam Physician. 2006;73:1961-1968.
15. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346:1221-1231.